No genetic cause or inheritance pattern is certified in this packet. Tumor histology is characterized by mixed blastemal, stromal, and epithelial elements constituting the nephroblastoma spectrum, as described in the disease definition.

No certified diagnostic methods are documented in this packet beyond histopathologic characterization. The disease definition describes mixed blastemal, stromal, and epithelial components as the defining microscopic features for subtype classification.

No FDA-approved therapies or foundational treatment regimens are certified in this packet. One orphan drug—liposome-encapsulated recombinant interleukin-2—holds an FDA designation for cancers of the kidney and renal pelvis; this designation is not specific to Wilms tumor. Active clinical trials are evaluating combination chemotherapy approaches and targeted cellular therapies, including CAR-T cell strategies.

Natural history data are not certified in this packet. The disease definition identifies the most common metastatic sites as regional lymph nodes, lungs, and liver.

ClinicalTrials.gov records 10 active or ongoing studies, including a Phase 3 randomized trial (NCT06401330) assessing risk-adapted treatment for favorable-histology Wilms tumor through the Children's Oncology Group, a Phase 2 combination chemotherapy study for diffuse anaplastic and relapsed Wilms tumor (NCT04322318), and two Phase 1 CAR-T cell studies (NCT04715191; NCT07172958). The research landscape encompasses 118 classified publications, with basic science and preclinical work as the dominant category, along with documented biomarker and gene therapy research.